Safety and efficacy of rivaroxaban versus warfarin in atrial fibrillation with stage 4 to 5 chronic kidney disease including dialysis

医学 拜瑞妥 心房颤动 肾脏疾病 内科学 华法林 心脏病学 透析 阶段(地层学) 抗凝剂 终末期肾病 血液透析 急性肾损伤 心力衰竭 疾病
作者
Anwar Almajdi,Sara Almutairi,Maha Alharbi
出处
期刊:Research and practice in thrombosis and haemostasis [Elsevier BV]
卷期号:10 (2): 103398-103398 被引量:2
标识
DOI:10.1016/j.rpth.2026.103398
摘要

Background Patients with atrial fibrillation (AF) and advanced chronic kidney disease (CKD) face elevated risks of stroke and bleeding; yet, optimal anticoagulation remains uncertain due to their exclusion from randomized trials. This systematic review and meta-analysis evaluated rivaroxaban vs warfarin in patients with AF and moderate-to-advanced CKD including dialysis. Methods We searched PubMed/MEDLINE, Embase, and Cochrane CENTRAL through August 2025 for observational studies comparing rivaroxaban with warfarin in adults with nonvalvular AF and CKD stages 4 to 5 including dialysis. Primary outcomes were stroke/systemic embolism and major bleeding. Pooled hazard ratios (HRs) were calculated using random-effects models. Risk of bias was assessed using ROBINS-I, and certainty of evidence was evaluated using GRADE. Results Four observational studies encompassing 31,037 patients of whom 12,160 received rivaroxaban and 18,877 received warfarin. Mean age ranged from 66 to 80 years, with CHA 2 DS 2 -VASc scores ranging from 3.5 to 4.5. Reduced-dose rivaroxaban (10-15 mg daily) was commonly prescribed. Compared with warfarin, rivaroxaban demonstrated a 30% reduction in stroke/systemic embolism (pooled HR, 0.70; 95% CI, 0.54-0.92; P = .009; I 2 = 38.1%) and 17% reduction in major bleeding (HR, 0.83; 95% CI, 0.72-0.97; P = .018). Favorable but nonsignificant trends were observed for intracranial hemorrhage (HR, 0.73; 95% CI, 0.49-1.08) and gastrointestinal bleeding (HR, 0.68; 95% CI, 0.46-1.03). Overall evidence quality was moderate according to GRADE assessment. Conclusion In patients with AF and advanced CKD including dialysis, rivaroxaban may be associated with improved efficacy and safety compared with warfarin. However, heterogeneity in CKD stages and off-label dosing practices necessitate prospective randomized trials to establish definitive treatment recommendations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Berry完成签到,获得积分10
1秒前
1秒前
1秒前
李健的应助被炘儿采纳,获得10
2秒前
2秒前
戒骄戒躁发布了新的文献求助10
2秒前
XxmG发布了新的文献求助10
2秒前
2秒前
2秒前
2秒前
bkagyin的应助被野荷采纳,获得10
2秒前
小马甲的应助被豆豆采纳,获得10
2秒前
3秒前
3秒前
无事小神仙完成签到 ,获得积分10
3秒前
单薄的烤鸡完成签到,获得积分20
3秒前
3秒前
搜集达人的应助被淡定的冷松采纳,获得10
4秒前
4秒前
隐形曼青的应助被捉闰土的猹采纳,获得10
4秒前
生菜发布了新的文献求助10
4秒前
llll完成签到,获得积分10
5秒前
小徐完成签到,获得积分10
5秒前
5秒前
球球了发布了新的文献求助10
6秒前
lcx关注了科研通微信公众号
6秒前
cc发布了新的文献求助10
7秒前
119911发布了新的文献求助10
7秒前
KONG完成签到,获得积分10
7秒前
无花果的应助被Code_king采纳,获得10
7秒前
梧wu完成签到,获得积分10
7秒前
7秒前
充电宝的应助被Code_king采纳,获得10
7秒前
zero1122发布了新的文献求助10
7秒前
领导范儿的应助被Code_king采纳,获得10
8秒前
8秒前
香蕉觅云的应助被Code_king采纳,获得10
8秒前
余香的应助被Code_king采纳,获得10
8秒前
研友_想想完成签到,获得积分10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176174
求助须知:如何正确求助?哪些是违规求助? 9567656
关于积分的说明 21793895
捐赠科研通 7770887
什么是DOI,文献DOI怎么找? 3431991
关于科研通互助平台的介绍 2556313
邀请新用户注册赠送积分活动 2477540